Metropolitan Life Insurance Company (MetLife)’s Larimar Therapeutics LRMR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,410	Closed	-$10.7K	–	1201
2024 Q1	$10.7K	Buy	+1,410	New	+$11K	﹤0.01%	2114
2018 Q4	–	Sell	-927	Closed	-$130K	–	2562
2018 Q3	$130K	Buy	+927	New	+$113K	﹤0.01%	2294
2015 Q4	–	Sell	-988	Closed	-$379K	–	2611
2015 Q3	$379K	Sell	988 -19	-2%	-$8.57K	﹤0.01%	1819
2015 Q2	$419K	Buy	+1,007	New	+$421K	﹤0.01%	1869
2015 Q1	–	Sell	-152	Closed	-$56K	–	2342
2014 Q4	$56K	Buy	+152	New	+$39.2K	﹤0.01%	2622

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LRMR Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Larimar Therapeutics (LRMR) in Q2 2024, closing a stake of 1,410 shares — an estimated $10.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LRMR in Q4 2014 and held it in 5 quarters. The position peaked at $419K in Q2 2015. 106 funds tracked by Wall St. Rank hold LRMR as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Larimar Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,410 Larimar Therapeutics shares in Q2 2024, an estimated $10.7K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Larimar Therapeutics in Q4 2014 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Larimar Therapeutics position peaked at $419K in Q2 2015.
106 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.